Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666.

Br J Cancer · 2023 · PMC10006228 · PMID 36631633

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

We think these results are highly significant and promising, considering that B16/F10-mOVA is an extremely aggressive tumour, and we are targeting it during the exponential phase of the tumour growth.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.